WO2004071394A2 - Agents de diagnostic et de traitement destines aux maladies associees a hm74 (hm74) - Google Patents

Agents de diagnostic et de traitement destines aux maladies associees a hm74 (hm74) Download PDF

Info

Publication number
WO2004071394A2
WO2004071394A2 PCT/EP2004/000885 EP2004000885W WO2004071394A2 WO 2004071394 A2 WO2004071394 A2 WO 2004071394A2 EP 2004000885 W EP2004000885 W EP 2004000885W WO 2004071394 A2 WO2004071394 A2 WO 2004071394A2
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
polypeptide
disorders
cancer
activity
Prior art date
Application number
PCT/EP2004/000885
Other languages
English (en)
Other versions
WO2004071394A3 (fr
Inventor
Stefan Golz
Ulf Brüggemeier
Holger Summer
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Priority to EP04707151A priority Critical patent/EP1597586A2/fr
Publication of WO2004071394A2 publication Critical patent/WO2004071394A2/fr
Publication of WO2004071394A3 publication Critical patent/WO2004071394A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un HM74 humain qui est associé aux troubles du système nerveux périphérique et central, aux maladies cardio-vasculaires, aux maladies hématologiques, au cancer, à l'inflammation, aux maladies respiratoires et aux maladies gastro-entérologiques. Cette invention se rapporte également à des dosages permettant d'identifier des composés utiles dans le traitement ou dans la prévention des troubles du système nerveux périphérique et central, des maladies cardio-vasculaires, des maladies hématologiques, du cancer, de l'inflammation, des maladies respiratoires et des maladies gastro-entérologiques. La présente invention concerne également des composés qui se lient à HM74 et/ou qui activent ou qui inhibent l'activité de HM74 ainsi que des compositions pharmaceutiques comprenant de tels composés.
PCT/EP2004/000885 2003-02-13 2004-01-31 Agents de diagnostic et de traitement destines aux maladies associees a hm74 (hm74) WO2004071394A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04707151A EP1597586A2 (fr) 2003-02-13 2004-01-31 Agents de diagnostic et de traitement destines aux maladies associees a hm74 (hm74)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003115.7 2003-02-13
EP03003115 2003-02-13

Publications (2)

Publication Number Publication Date
WO2004071394A2 true WO2004071394A2 (fr) 2004-08-26
WO2004071394A3 WO2004071394A3 (fr) 2005-01-20

Family

ID=32864931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/000885 WO2004071394A2 (fr) 2003-02-13 2004-01-31 Agents de diagnostic et de traitement destines aux maladies associees a hm74 (hm74)

Country Status (2)

Country Link
EP (1) EP1597586A2 (fr)
WO (1) WO2004071394A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US7700597B2 (en) 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056820A1 (fr) * 1997-06-12 1998-12-17 Smithkline Beecham Corporation Recepteur hm74a
WO2001073029A2 (fr) * 2000-03-27 2001-10-04 Pe Corporation (Ny) Recepteurs couples aux proteines g humaines isolees, molecules d'acides nucleiques codant les proteines gpcr humaines, et utilisations correspondantes
WO2001077320A2 (fr) * 2000-04-05 2001-10-18 Bayer Aktiengesellschaft Regulation du recepteur couple aux proteines g humain du type hm74
WO2001094385A2 (fr) * 2000-06-05 2001-12-13 Bayer Aktiengesellschaft Regulation du recepteur couple a la proteine humaine g de type hm74
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021484D0 (en) * 2000-09-01 2000-10-18 Boehringer Ingelheim Pharma Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056820A1 (fr) * 1997-06-12 1998-12-17 Smithkline Beecham Corporation Recepteur hm74a
WO2001073029A2 (fr) * 2000-03-27 2001-10-04 Pe Corporation (Ny) Recepteurs couples aux proteines g humaines isolees, molecules d'acides nucleiques codant les proteines gpcr humaines, et utilisations correspondantes
WO2001077320A2 (fr) * 2000-04-05 2001-10-18 Bayer Aktiengesellschaft Regulation du recepteur couple aux proteines g humain du type hm74
WO2001094385A2 (fr) * 2000-06-05 2001-12-13 Bayer Aktiengesellschaft Regulation du recepteur couple a la proteine humaine g de type hm74
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1597586A2 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US7371822B2 (en) 2003-03-14 2008-05-13 Bristol-Myers Squibb Company Human G-protein coupled receptor variant of HM74, HGPRBMY74
US7700597B2 (en) 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists

Also Published As

Publication number Publication date
WO2004071394A3 (fr) 2005-01-20
EP1597586A2 (fr) 2005-11-23

Similar Documents

Publication Publication Date Title
WO2003081258A2 (fr) Diagnostics et elements therapeutiques pour maladies associees au recepteur secretagogue de l'hormone de croissance (ghs)
WO2003074069A2 (fr) Diagnostic et therapeutique destines a des maladies associees au recepteur peptidique n-formyl 1 (fpr1)
WO2004080373A2 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 2 active par la proteinase (par2) couple aux proteines g
US7465548B2 (en) Methods of screening for potential therapeutics for diseases associated with G-protein coupled receptor HM74a
WO2004042402A2 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees au mrgx1 humain
EP1369698A1 (fr) Méthodes de diagnostic et de traitment de maladies associées au récepteur de la somatostatine 5 (SSTR5)
WO2004038405A2 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 43 couple a la proteine g (gpr43)
US20060257405A1 (en) Diagnostics and therapeutics for diseases associated with aryl hydrocarbon receptor (ahr)
US20060240013A1 (en) Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37)
WO2004044580A1 (fr) Diagnostics et thérapeutiques destinés à des maladies associées au récepteur humain 2 couplé aux protéines g (edg2) d'acide lysophosphatidique, de différentiation endothéliale
WO2004082571A2 (fr) Diagnostics et therapies pour maladies associees au recepteur 86 couple a la proteine g (gpr86)
WO2004038421A2 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 41 couple a une proteine g humaine (gpr41)
WO2003104817A1 (fr) Diagnostics et moyens therapeutiques pour des maladies associees au recepteur 4 (sstr4) de somatostatine
EP1597586A2 (fr) Agents de diagnostic et de traitement destines aux maladies associees a hm74 (hm74)
WO2005003762A2 (fr) Procedes pour diagnostiquer et traiter des maladies associees au recepteur 2 couple a la proteine g specifique aux neurones sensoriels (snsr2)
WO2004072648A1 (fr) Moyens pour diagnostiquer et traiter des maladies associees au recepteur ox2r couple a la proteine g (ox2r)
WO2005095990A1 (fr) Methodes diagnostiques et therapeutiques pour des maladies associees au recepteur 52 couple a la proteine g (gpr52)
WO2004097422A2 (fr) Diagnostic et traitement de maladies associees au recepteur de la calcitonine (calcr)
WO2004082572A2 (fr) Diagnostics et therapies pour les maladies associees au recepteur 87 couple a la proteine g (gpr87)
WO2004038416A1 (fr) Diagnostic et therapeutique de maladies associees au recepteur 6 couple a la proteine g humain (gpr6)
WO2003080097A2 (fr) Methodes diagnostiques et therapeutiques relatives a des maladies associees au recepteur 7 couple a la proteine g humaine (gpr7)
WO2004042405A2 (fr) Diagnostic et therapeutique pour maladies associees au recepteur 3 couples aux proteines g (gpr3) humain
WO2004106936A2 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au purinorecepteur p2y9 couple aux proteines g
EP1597582A2 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 3 couple a une proteine g sphingolipide de differenciation endotheliale humain (edg3)
WO2005093425A2 (fr) Diagnostic et traitement de maladies associees au recepteur couple aux proteines g 58 (gpr58)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004707151

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004707151

Country of ref document: EP